



SalvaRx Group plc - SALV Update re proposed disposal and demerger
Released 17:40 28-Aug-2018

RNS Number : 0548Z
SalvaRx Group plc
28 August 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Update re proposed disposal and demerger

Further to the announcement of 14 August 2018 relating to the proposed disposal of the Company's 94.2 per cent. interest in its subsidiary SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company has been informed that the Portage shareholder circular has now been submitted to the Canadian Securities Exchange ("CSE") for review. Following completion of the CSE review, both Portage and the Company will publish their respective shareholder circulars and a further announcement will be made by the Company.

Enquiries

SalvaRx Group plc

Ian B. Walters, MD (Chief Executive)

Tel: +1 203 441 5451

Northland Capital Partners Limited

Tel: +44 (0) 20 3861 6625

Nominated Adviser and Broker

Matthew Johnson / Edward Hutton (Corporate Finance)

Vadim Alexandre (Corporate Broking)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDFMGZRVRNGRZM

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

Update re proposed disposal and demerger - RNS